Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the response rate to neoadjuvant Compound 121564 plus
platinum doublet chemotherapy in patients with early stage non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Arafat Tfayli
Collaborators:
Merck KGaA Merck KGaA, Darmstadt, Germany Phoenix Clinical Research